Published in Eur J Cancer on October 01, 1976
Soluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis. Thromb J (2006) 0.85
Peri-operative heparin: a possible adjuvant to surgery in colo-rectal cancer? Int J Colorectal Dis (1993) 0.81
Extrapulmonary colony formation after intravenous injection of tumour cells into heparin-treated animals. Br J Cancer (1978) 0.80
Aspirin for reducing cancer metastases? J Natl Med Assoc (1977) 0.77
Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms. J Cancer Res Clin Oncol (2016) 0.76
The rarity of liver toxicity in patients treated with coumarin (1,2-benzopyrone). Hum Toxicol (1989) 1.78
Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 1.58
The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev (1990) 1.40
Inhibition of locomotion of cancer cells in vivo by anticoagulant therapy. I. Effects of sodium warfarin on V2 cancer cells, granulocytes, lymphocytes and macrophages in rabbits. Johns Hopkins Med J (1968) 1.33
Prostacyclin deficiency in thrombotic thrombocytopenic purpura. Lancet (1979) 1.27
Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer (1977) 1.26
The effects of proteolysis on the human immune mechanism in cancer. A preliminary communication. J Med (1974) 1.19
Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol (2010) 1.16
The effect of heparin on the initial phase of metastasis formation. Eur J Cancer (1972) 1.15
Experimental hypercalcaemia and whole blood clotting. J Clin Pathol (1973) 1.10
Cimetidine and coumarin therapy of melanoma. Lancet (1982) 1.02
Oral anticoagulation in the treatment of a spontaneously metastasising murine tumour (3LL). Br J Cancer (1977) 1.01
Ifosfamide--current aspects and perspectives. Cancer Treat Rev (1983) 1.01
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. Acta Oncol (1989) 0.99
The role of blood platelets in experimental metastases. Br J Cancer (1973) 0.95
Microangiopathic haemolytic anaemia and experimental tumour-cell emboli. Br J Haematol (1974) 0.94
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Prog Exp Tumor Res (1992) 0.93
D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport. Cancer Chemother Pharmacol (1995) 0.93
Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols. J Cancer Res Clin Oncol (1984) 0.92
The influence of platelet aggregation inhibitors on metastasis formation in mice (3LL). Z Krebsforsch Klin Onkol Cancer Res Clin Oncol (1976) 0.92
Gene trapping identifies inhibitors of oncogenic transformation. The tissue inhibitor of metalloproteinases-3 (TIMP3) and collagen type I alpha2 (COL1A2) are epidermal growth factor-regulated growth repressors. J Biol Chem (1998) 0.91
Microangiopathic haemolytic anaemia associated with hypercalcaemia in an experimental rat tumour. Br J Haematol (1973) 0.90
Acute hypercalcemia due to Walker carcinosarcoma 256 in the rat. Horm Metab Res (1970) 0.89
Aspirin and tumour metastasis. Lancet (1972) 0.89
Platelet shape change abnormalities in diabetic retinopathy. Diabetologia (1980) 0.88
Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. Rofo (2010) 0.87
Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat (1992) 0.87
A novel casein kinase 2 alpha-subunit regulates membrane protein traffic in the human hepatoma cell line HuH-7. J Biol Chem (2000) 0.87
Acquired immune suppression in chronic brucellosis. Ir Med J (1983) 0.87
Factor X-activating activity from Lewis lung carcinoma. Br J Cancer (1980) 0.87
[Intravascular coagulation in solid Walker carcinosarcoma 256]. Schweiz Med Wochenschr (1971) 0.84
Mechanism of lung tumour colony reduction caused by coumarin anticoagulation. Eur J Cancer (1979) 0.84
Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. Oncogene (1996) 0.84
[Hypercalcemic activity of Walker carcinosarcoma 256 in the rat]. Schweiz Med Wochenschr (1971) 0.84
The anergy of chronic human brucellosis. Ir Med J (1977) 0.83
Opposite effect of miltefosine on the antineoplastic activity and haematological toxicity of cyclophosphamide. Eur J Cancer (1995) 0.83
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treat Rev (1990) 0.82
Letter: Plasmapheresis and immunostimulation. Lancet (1976) 0.81
The tetrazolium dye assay for rapid in vitro assessment of cytotoxicity. Arzneimittelforschung (1989) 0.80
Molecular and cellular effects of hexadecylphosphocholine (Miltefosine) in human myeloid leukaemic cell lines. Eur J Cancer (1994) 0.80
Unblocking or activation of the cellular immune mechanism by induced proteolysis in patients with cancer. Lancet (1974) 0.80
Analysis of coumarin and its urinary metabolites by high-performance liquid chromatography. J Chromatogr (1987) 0.80
Thrombin-induced disseminated intravascular coagulation. III:Modification by dextran infusion. Br J Anaesth (1975) 0.79
Chronic brucellosis--clinical response to reduction of suppressor T lymphocytes by cyclophosphamide/prednisone. Ir Med J (1982) 0.79
Synthesis of procoagulant antihaemophilic factor in vitro. Lancet (1979) 0.79
Anticoagulants and experimental metastases-evaluation of antimetastatic effects in different model systems. J Cancer Res Clin Oncol (1981) 0.79
The enhancing influence of proteolysis on E rosette forming lymphocytes (T cells) in vivo and in vitro. Br J Cancer (1975) 0.79
Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone. J Cancer Res Clin Oncol (1992) 0.79
Current development of podophyllotoxins. Cancer Chemother Pharmacol (1982) 0.78
Chronic human brucellosis and anti-anergic treatment with levamisole. Vet Rec (1977) 0.78
Etoposide--chemistry, preclinical and clinical pharmacology. Cancer Treat Rev (1982) 0.78
Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol (1984) 0.78
The use of the proteolytic enzyme brinase to produce autocytotoxicity in patients with acute leukemia and its possible role in immunotherapy. Cancer Res (1972) 0.78
Oxazaphosphorines as biological response modifiers--experimental and clinical perspectives. Cancer Treat Rev (1985) 0.78
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial. Onkologie (1988) 0.78
Adjuvant therapy of cancer via the cellular immune mechanism or fibrin by induced fibrinolysis and oral anticoagulants. Cancer (1975) 0.78
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro. Eur J Cancer (1993) 0.78
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. Clin Nephrol (2011) 0.78
[The cytotoxic effect of plasmin on yoshida sarcoma cells]. Z Krebsforsch (1969) 0.77
The key role of hydroxylation for the cytostatic activity and selectivity of cyclophosphamide. Invest New Drugs (1984) 0.77
Highly sensitive northern hybridization of rare mRNA using a positively charged nylon membrane. Biotechniques (1994) 0.77
A critical analysis of the use of sialic acid determination in the diagnosis of malignancy. Cancer Lett (1991) 0.77
Biotransformation of mafosfamide in P388 mice leukemia cells: intracellular 31P-NMR studies. Biochim Biophys Acta (1990) 0.77
The antitumor activity of the platinum complex D-17872 is associated with tumor cell differentiation. Cancer Chemother Pharmacol (1993) 0.77
Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models. Cancer Immunol Immunother (1989) 0.77
D-19466, a new cyclobutane-platinum complex with antitumor activity. J Cancer Res Clin Oncol (1990) 0.77
Studies of human serum amyloid P-component (SAP) in relation to coagulation. Clin Chim Acta (1980) 0.77
Selection and characterization of mammalian cell lines with stable over-expression of human pituitary receptors for gonadoliberin. Eur J Biochem (1995) 0.77
A new platelet aggregating material (PAM) in an experimentally induced rat fibrosarcoma. Thromb Haemost (1984) 0.77
Inhibition of antiplasmin, and effect of protease I in patients with leukaemia. Lancet (1968) 0.77
Pharmacological studies with cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone. Eur J Cancer (1996) 0.77
[Selective internal radiotherapy (SIRT) for hepatocellular carcinoma]. Rofo (2010) 0.77
Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg----His): fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost (1986) 0.77
Oral anticoagulant therapy of human cancer. J Med (1974) 0.77
Basis and new developments in the field of oxazaphosphorines. Cancer Invest (1988) 0.77
[Fibrinogen elevation in malignant tumors--an unspecific symptom]. Verh Dtsch Ges Inn Med (1969) 0.77
Antiinvasive activity of hexadecylphosphocholine in vitro. Anticancer Res (1991) 0.76
Induction of tumor cell differentiation by alkylphosphocholines: a new approach for in vitro screening. Prog Exp Tumor Res (1992) 0.76
Liver transplantation for hepatocellular carcinoma after yttrium therapy: a case report. Transplant Proc (2008) 0.76
Necrosis of the skin induced by coumarin. BMJ (1989) 0.75
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol (1993) 0.75
Prevention of ultraviolet-light-induced herpes labialis. Lancet (1992) 0.75
Coumarin and cimetidine in malignant melanoma. Ir Med J (1983) 0.75
Control of blow fly strike in sheep by coumarin. Vet Rec (1991) 0.75
Increased potassium in lymphocytes from patients with chronic lymphatic leukaemia. Br J Cancer (1973) 0.75
Mechanisms of C. Parvum-induced coagulopathy in mice. Br J Cancer (1980) 0.75
Fibrin and cancer. Br Med J (1972) 0.75
Physiology of fibrinolysis. 3. The effect of exercise on fibrinolysis in health and multiple sclerosis. Ir J Med Sci (1968) 0.75
Letter: Activation or unblocking of T lymphocytes. Lancet (1974) 0.75
Subclavian or jugular vein catheters. Lancet (1972) 0.75
Locoregional therapy for hepatocellular carcinoma: radioembolization with yttrium-90 microspheres. Minerva Gastroenterol Dietol (2011) 0.75
B.C.G. plus protease L in malignant melanoma. Lancet (1973) 0.75
The Graves lecture, 1966. Host factors in neoplasia. Ir J Med Sci (1966) 0.75
The effects of protease I of Aspergillus oryzae (brinase) on membrane permeability and growth of Landschütz ascites tumour cells. Int J Cancer (1971) 0.75
The physiology of fibrinolysis. II. Antiplasmin. Ir J Med Sci (1967) 0.75
Letter: Immunological control of cancer. Lancet (1975) 0.75
Anticoagulant therapy in patients with cancer. J Ir Med Assoc (1969) 0.75
Effect of oral streptokinase on antibody and antiplasmin levels. Lancet (1966) 0.75
The thrombolytic action of protease 1 on experimentally produced venous thrombi in the dog. Ir J Med Sci (1969) 0.75
Complement dependent cytotoxic autoantibodies in patients with acute leukaemia following fibrinolytic therapy by protease 1 of aspergillus oryzae. Ir J Med Sci (1970) 0.75